ClinicalTrials.gg
CompletedNCT04428151Updated Dec 4, 2025Results posted

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

A Phase 2 interventional study of Lenvatinib and Pembrolizumab in Squamous Cell Carcinoma of Head and Neck, sponsored by Merck Sharp & Dohme LLC. Completed at 120 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck — 18 open to participants now, 32 under way, 2 of them phase 3. pembrolizumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
2nd of 63
408 · median 50
Started
2020
with 4 others
Phase 2
44 of 63
14 open now
Registered
31st of 63
by date
Lead sponsor
4 of 63
Merck Sharp & Dohme LLC

Among the 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 2nd largest by enrollment, is one of 5 that started in 2020, is one of 44 in phase 2, and was the 31st registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

18 of the 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 5 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic). Some people with recurrent or metastatic head and neck cancer are treated with chemotherapy and immunotherapy, but the cancer gets worse.

The goal of this study is to learn if more people who receive lenvatinib and pembrolizumab have a better overall survival rate than people who receive standard chemotherapy treatment.

Read the detailed description

With Amendment 7, participants will discontinue lenvatinib and pembrolizumab and lenvatinib monotherapy, unless discussed with the Sponsor.

A protocol-specified periodic safety review was completed with a data cut-off of 31-May-2024 (Primary Completion Date) and served as the final analysis of the primary outcome measure. Per protocol, 34 participants enrolled after the primary completion date and will be analyzed in the End of Trial analysis.

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed recurrent (not amenable to curative treatment with local and/or systemic therapies) or (disseminated) head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, and/or larynx that is considered incurable by local therapies
  • Disease progression at any time during or after treatment with a platinum-containing (e.g., carboplatin or cisplatin) regimen
  • Disease progression on or after treatment with a programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody (/PD-L1 mAb)
  • Pre-study imaging that demonstrates evidence of disease progression based on investigator review of at least 2 pre-study images per 1.1, following initiation of treatment with a PD-1/PD-L1 inhibitor
  • by computed tomography scan (CT) or magnetic resonance imaging (MRI) based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as verified by blinded independent central review (BICR). Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  • (ECOG) performance status of 0 or 1 assessed within 7 days of the first dose of study intervention
  • Male participants are eligible to participate if they agree to the following during the intervention period and for at least 1 week after the last dose of lenvatinib, 3 months after the last dose of capecitabine and paclitaxel, and 6 months after the last dose of docetaxel:

    • Refrain from donating sperm
    • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use unless confirmed to be azoospermic
    • Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

    • Is not a woman of (WOCBP)
    • Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days post pembrolizumab or 1 month post lenvatinib, whichever occurs last (Arms 1 and 3), or during the intervention period and for at least 6 months after the last dose of capecitabine, docetaxel, paclitaxel; and 2 months after the last dose of cetuximab (Arm 2)
    • Female participants who randomize to Arm 2 must also agree not to donate or freeze/store eggs during the intervention period and for at least 6 months after the last dose of capecitabine, docetaxel, paclitaxel; and 2 months after the last dose of cetuximab
  • Adequately controlled blood pressure (BP) with or without antihypertensive medications
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
  • Participants with history of virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Disease that is suitable for local therapy administered with curative intent
  • of less than 3 months and/or has rapidly progressing disease in the opinion of the treating investigator
  • History of (noninfectious) pneumonitis/interstitial lung disease that required , or has current pneumonitis/interstitial lung disease
  • Active infection requiring systemic therapy
  • Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study drug
  • Known active central nervous system (CNS) and/or carcinomatous meningitis
  • Known additional that is progressing or has required active systemic treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ that have undergone potentially curative therapy
  • Active disease that has required systemic treatment in the past 2 years
  • Had an allogeneic tissue/solid organ transplant
  • Known history of (HIV) infection
  • History of any or has a severe to any components of pembrolizumab, lenvatinib or SOC chemotherapy.
  • Pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula
  • History of a gastrointestinal malabsorption or any other condition or procedure that may affect oral study drug absorption
  • Had major surgery within 3 weeks prior to first dose of study interventions
  • cardiovascular impairment within 12 months of the first dose of study drug
  • Active tuberculosis
  • Has difficulty swallowing capsules or ingesting a suspension orally, or by a feeding tube
  • Prior treatment with lenvatinib
  • Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1 or has not recovered from adverse events (AEs) due to a previously administered agent. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible
  • Has received a live or within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines is allowed
  • Previously treated with 4 or more systemic regimens given for recurrent/metastatic disease
  • Has received an agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    Lenvatinib + Pembrolizumab

    Participants will be treated with the combination of lenvatinib (once daily 20 mg oral dose) plus pembrolizumab (200 mg 30-minute intravenous (IV) infusion on Day 1 of each 21-day cycle for 35 cycles), until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met. Participants may receive up to an additional 17 cycles of pembrolizumab as Second Course treatment, with or without lenvatinib.

    Drug: Lenvatinib · Biological: Pembrolizumab

  • Active comparator
    SOC Chemotherapy

    Participants will be treated with investigator's choice of standard of care (SOC) chemotherapy (docetaxel, paclitaxel, cetuximab, or capecitabine) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.

    Drug: Docetaxel · Drug: Capecitabine · Drug: Paclitaxel · Drug: Cetuximab

  • Active comparator
    Lenvatinib Monotherapy

    Participants will be treated with lenvatinib monotherapy (once daily 24 mg oral dose) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.

    Drug: Lenvatinib

Interventions

  • 20 mg once daily, taken as oral capsules

    Also known as: LENVIMA®, MK-7902, E7080

  • BiologicalPembrolizumab

    200 mg 30-minute IV infusion on day 1 of each 21-day cycle

    Also known as: KEYTRUDA®, MK-3475, SCH 900475

  • 75 mg/m\^2 administered as an IV infusion on day 1 of each 21-day cycle

    Also known as: TAXOTERE®

  • 1250 mg/m\^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets

    Also known as: Xeloda®

  • 80 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle

    Also known as: Taxol

  • 400 mg/m\^2 loading dose, followed by 250 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle

    Also known as: ERBITUX®

  • 24 mg once daily, taken as oral capsules

    Also known as: LENVIMA®, MK-7902, E7080

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 45 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD.

    Time frame: Up to approximately 45 months

  2. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who had a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to approximately 45 months

  3. Duration of Response (DOR)

    DOR was defined as the time from the first documented evidence of complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR.

    Time frame: Up to approximately 45 months

  4. Number of Participants Who Experienced One or More Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE was presented.

    Time frame: Up to approximately 5 years

  5. Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE was presented.

    Time frame: Up to approximately 5 years

07

Results

Posted May 25, 2025

Participant flow

Participant flow — Overall Study
MilestoneLenvatinib + PembrolizumabSOC ChemotherapyLenvatinib Monotherapy
Started14414288
Treated14314088
Switched over to pembrolizumab + lenvatinib06118
Switched over to pembrolizumab010
Completed000
Not completed14414288
Withdrew: Death1008657
Withdrew: Lost to follow-up110
Withdrew: Withdrawal by subject223
Withdrew: Participant ongoing in study415328

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 45 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsLenvatinib + PembrolizumabSOC ChemotherapyLenvatinib Monotherapy
Overall Survival (OS)8.4 (6.9 to 10.3)11.3 (9.8 to 14.4)—
Statistical analysis
  • Lenvatinib + Pembrolizumab vs SOC Chemotherapy · Log Rank · p = 0.9963 (One-sided p-value based on log-rank test stratified by baseline PD-L1 TPS (\<50% versus ≥50%) and baseline ECOG performance status (0 versus 1). The reported p-value is nominal.) · Hazard ratio (hr): 1.48 · 95% CI 1.11 to 1.97Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by baseline PD-L1 TPS (\<50% versus ≥50%) and baseline ECOG performance status (0 versus 1).
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD.

Time frame:
Up to approximately 45 months
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsLenvatinib + PembrolizumabSOC ChemotherapyLenvatinib Monotherapy
Progression-Free Survival (PFS)3.0 (2.8 to 3.9)2.8 (2.6 to 4.0)—
Statistical analysis
  • Lenvatinib + Pembrolizumab vs SOC Chemotherapy · Log Rank · p = 0.4181 (One-sided p-value based on log-rank test stratified by baseline PD-L1 TPS (\<50% versus ≥50%) and baseline ECOG performance status (0 versus 1). The reported p-value is nominal.) · Hazard ratio (hr): 0.97 · 95% CI 0.74 to 1.28Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by baseline PD-L1 TPS (\<50% versus ≥50%) and baseline ECOG performance status (0 versus 1).
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who had a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to approximately 45 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsLenvatinib + PembrolizumabSOC ChemotherapyLenvatinib Monotherapy
Objective Response Rate (ORR)13.9 (8.7 to 20.6)20.4 (14.1 to 28.0)—
Statistical analysis
  • Lenvatinib + Pembrolizumab vs SOC Chemotherapy · Miettinen & Nurminen · p = 0.9266219 · Difference in percentage: -6.5 · 95% CI -15.4 to 2.3Based on Miettinen \& Nurminen method stratified by baseline PD-L1 TPS (\<50% versus ≥50%) and baseline ECOG performance status (0 versus 1).
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first documented evidence of complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR.

Time frame:
Up to approximately 45 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsLenvatinib + PembrolizumabSOC ChemotherapyLenvatinib Monotherapy
Duration of Response (DOR)4.1 (3.6 to 7.9)5.9 (3.7 to 11.8)—
SecondaryNumber of Participants Who Experienced One or More Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE was presented.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE was presented.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

Adverse events

Collected over Up to approximately 45 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib + Pembrolizumab103/144 (71.5%)86/143 (60.1%)139/143 (97.2%)
SOC Chemotherapy42/142 (29.6%)57/140 (40.7%)135/140 (96.4%)
Lenvatinib Monotherapy50/88 (56.8%)45/88 (51.1%)80/88 (90.9%)
SOC Chemotherapy Switched Over to Pembrolizumab+Lenvatinib44/61 (72.1%)27/61 (44.3%)55/61 (90.2%)
SOC Chemotherapy Switched Over to Pembrolizumab1/1 (100%)1/1 (100%)1/1 (100%)
Lenvatinib Switched Over to Pembrolizumab+Lenvatinib10/18 (55.6%)6/18 (33.3%)15/18 (83.3%)
Most frequent serious events
Showing 10 of 169
Most frequent serious events
EventLenvatinib + PembrolizumabSOC ChemotherapyLenvatinib MonotherapySOC Chemotherapy Switched Over to Pembrolizumab+LenvatinibSOC Chemotherapy Switched Over to PembrolizumabLenvatinib Switched Over to Pembrolizumab+Lenvatinib
PneumoniaInfections and infestations20/1438/1404/885/611/12/18
SepsisInfections and infestations3/1431/1401/881/610/12/18
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/1433/1406/881/610/11/18
Cardiac tamponadeCardiac disorders0/1430/1400/880/610/11/18
Upper gastrointestinal haemorrhageGastrointestinal disorders0/1430/1400/880/610/11/18
Large intestine infectionInfections and infestations0/1430/1400/880/610/11/18
HypotensionVascular disorders0/1430/1400/880/610/11/18
DysphagiaGastrointestinal disorders4/1432/1403/883/610/10/18
PyrexiaGeneral disorders1/1431/1400/883/610/10/18
Pneumonia aspirationInfections and infestations4/1432/1402/883/610/10/18
Most frequent other events
Showing 10 of 103
Most frequent other events
EventLenvatinib + PembrolizumabSOC ChemotherapyLenvatinib MonotherapySOC Chemotherapy Switched Over to Pembrolizumab+LenvatinibSOC Chemotherapy Switched Over to PembrolizumabLenvatinib Switched Over to Pembrolizumab+Lenvatinib
Urinary tract infectionInfections and infestations9/1432/1404/882/611/10/18
Alanine aminotransferase increasedInvestigations11/1438/1405/882/611/11/18
Aspartate aminotransferase increasedInvestigations13/14311/1409/886/611/12/18
HyponatraemiaMetabolism and nutrition disorders8/1434/1409/881/611/12/18
Urinary retentionRenal and urinary disorders1/1432/1401/880/611/10/18
HypertensionVascular disorders60/1435/14034/8817/611/11/18
StomatitisGastrointestinal disorders52/14328/14026/8821/610/11/18
HypothyroidismEndocrine disorders49/14312/14028/8815/610/11/18
Weight decreasedInvestigations26/14322/14027/887/610/12/18
DiarrhoeaGastrointestinal disorders38/14326/14025/8815/610/14/18

Baseline characteristics

Per protocol, analysis population consisted of all participants randomized by the primary completion data cut-off.

Age, Continuous
Age, Continuous(Years)Lenvatinib + PembrolizumabSOC ChemotherapyLenvatinib MonotherapyTotal
Mean62.3 ± 9.061.4 ± 10.059.9 ± 9.361.4 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib + PembrolizumabSOC ChemotherapyLenvatinib MonotherapyTotal
Female18191451
Male12612374323
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib + PembrolizumabSOC ChemotherapyLenvatinib MonotherapyTotal
Hispanic or Latino33612
Not Hispanic or Latino13913782358
Unknown or Not Reported2204
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib + PembrolizumabSOC ChemotherapyLenvatinib MonotherapyTotal
American Indian or Alaska Native1236
Asian354025100
Native Hawaiian or Other Pacific Islander0000
Black or African American2428
White1049657257
More than one race0000
Unknown or Not Reported2013
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Lenvatinib + PembrolizumabSOC ChemotherapyLenvatinib MonotherapyTotal
ECOG = 0525832142
ECOG = 1928456232
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline(Participants)Lenvatinib + PembrolizumabSOC ChemotherapyLenvatinib MonotherapyTotal
TPS = <50%12112074315
TPS = ≥ 50%23221459
08

Study locations

120 sites
  • City of Hope ( Site 1519)
    Duarte, California 91010, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1568)
    Los Angeles, California 90095, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 1505)
    New Haven, Connecticut 06510, United States
  • Georgetown University Medical Center ( Site 1520)
    Washington D.C., District of Columbia 20007, United States
  • UF Health ( Site 1554)
    Gainesville, Florida 32608, United States
  • Mid Florida Hematology and Oncology Center ( Site 1606)
    Orange City, Florida 32763, United States
  • Cleveland Clinic Florida ( Site 1596)
    Weston, Florida 33331, United States
  • Georgia Cancer Center at Augusta University ( Site 1575)
    Augusta, Georgia 30912, United States
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1521)
    Marietta, Georgia 30060, United States
  • Memorial Health University Medical Center ( Site 1626)
    Savannah, Georgia 31404, United States
  • Beacon Cancer Care ( Site 1599)
    Post Falls, Idaho 83854, United States
  • Rush University Medical Center ( Site 1560)
    Chicago, Illinois 60607, United States
  • NorthShore University HealthSystem - Evanston Hospital ( Site 1614)
    Evanston, Illinois 60201, United States
  • IU Health Ball Memorial Hospital, Inc.-IU Health Ball Memorial Cancer Center ( Site 1612)
    Muncie, Indiana 47303, United States
  • University of Iowa ( Site 1572)
    Iowa City, Iowa 52242, United States
  • University of Kansas Cancer Center ( Site 1538)
    Westwood, Kansas 66205, United States
  • Norton Hospital-Norton Cancer Institute - Downtown ( Site 1601)
    Louisville, Kentucky 40205, United States
  • Mercy Health-Paducah Cancer Center ( Site 1623)
    Paducah, Kentucky 42003, United States
  • Our Lady of the Lake RMC-Clinical Research ( Site 1624)
    Baton Rouge, Louisiana 70808, United States
  • Mary Bird Perkins Cancer Center Baton Rouge ( Site 1622)
    Baton Rouge, Louisiana 70809, United States
  • University of Maryland Greenebaum Cancer Center ( Site 1522)
    Baltimore, Maryland 21201, United States
  • Boston Medical Center ( Site 1605)
    Boston, Massachusetts 02118, United States
  • University of Massachusetts Chan Medical School ( Site 1616)
    Worcester, Massachusetts 01655, United States
  • VA Ann Arbor Healthcare System ( Site 1584)
    Ann Arbor, Michigan 48105, United States
  • Barbara Ann Karmanos Cancer Institute ( Site 1566)
    Detroit, Michigan 48201, United States
  • Henry Ford Health System ( Site 1544)
    Detroit, Michigan 48202, United States
  • Hattiesburg Clinic ( Site 1515)
    Hattiesburg, Mississippi 39401, United States
  • Jackson Oncology Associates, PLLC-Clinical Trials ( Site 1625)
    Jackson, Mississippi 39202, United States
  • Washington University School of Medicine ( Site 1500)
    St Louis, Missouri 63110, United States
  • St. Vincent Frontier Cancer Center ( Site 1507)
    Billings, Montana 59102, United States
  • University Of Nebraska Medical Center ( Site 1570)
    Omaha, Nebraska 68105, United States
  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 1627)
    Omaha, Nebraska 68130, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1555)
    Hackensack, New Jersey 07601, United States
  • Rutgers Cancer Institute of New Jersey ( Site 1523)
    New Brunswick, New Jersey 08901, United States
  • Perlmutter Cancer Center at Winthrop Oncology Hematology Associates NYU Langone Health ( Site 1597)
    Mineola, New York 11501, United States
  • Laura and Isaac Perlmutter Cancer Center ( Site 1582)
    New York, New York 10016, United States
  • Levine Cancer Institute ( Site 1590)
    Charlotte, North Carolina 28204, United States
  • Duke Cancer Institute ( Site 1541)
    Durham, North Carolina 27710, United States
  • University of Cincinnati Medical Center ( Site 1567)
    Cincinnati, Ohio 45219, United States
  • University Hospital Cleveland ( Site 1578)
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Main ( Site 1598)
    Cleveland, Ohio 44195, United States
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 1558)
    Columbus, Ohio 43210, United States
  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1508)
    Tulsa, Oklahoma 74146, United States
  • Gettysburg Cancer Center ( Site 1594)
    Gettysburg, Pennsylvania 17325, United States
  • Penn State Hershey Medical Center ( Site 1561)
    Hershey, Pennsylvania 17033, United States
  • Fox Chase Cancer Center ( Site 1502)
    Philadelphia, Pennsylvania 19111, United States
  • Medical University of South Carolina ( Site 1579)
    Charleston, South Carolina 29425, United States
  • St Francis Cancer Center-Research Office ( Site 1607)
    Greenville, South Carolina 29607, United States
  • The Center For Cancer And Blood Disorders ( Site 1569)
    Fort Worth, Texas 76104, United States
  • Utah Cancer Specialists ( Site 1621)
    Salt Lake City, Utah 84106, United States
  • Huntsman Cancer Institute ( Site 1532)
    Salt Lake City, Utah 84112, United States
  • Inova Schar Cancer Institute ( Site 1550)
    Fairfax, Virginia 22031-4867, United States
  • Hematology Oncology Associates of Fredericksburg ( Site 1537)
    Fredericksburg, Virginia 22408, United States
  • MultiCare Health System-MultiCare Oncology - Puget Sound ( Site 1609)
    Tacoma, Washington 98405, United States
  • Medical College of Wisconsin Clinical Cancer Center ( Site 1574)
    Milwaukee, Wisconsin 53226, United States
  • Mid North Coast Cancer Institute ( Site 0109)
    Port Macquarie, New South Wales 2444, Australia
  • Blacktown Hospital ( Site 0101)
    Sydney, New South Wales 2148, Australia
  • The Townsville Hospital ( Site 0107)
    Douglas, Queensland 4814, Australia
  • Gallipoli Medical Research Ltd-GMRF CTU ( Site 0105)
    Greenslopes, Queensland 4120, Australia
  • Royal Adelaide Hospital ( Site 0110)
    Adelaide, South Australia 5000, Australia
  • Monash Health ( Site 0102)
    Clayton, Victoria 3168, Australia
  • Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0806)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • A. C. Camargo Cancer Center ( Site 0809)
    São Paulo, 01509-010, Brazil
  • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0304)
    Calgary, Alberta T2N 5G2, Canada
  • BC Cancer-Vancouver Center ( Site 0306)
    Vancouver, British Columbia V5Z 4E6, Canada
  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0307)
    Hamilton, Ontario L8V 5C2, Canada
  • Sunnybrook Research Institute ( Site 0308)
    Toronto, Ontario M4N 3M5, Canada
  • Instituto de Cancerología ( Site 0408)
    Medellín, Antioquia 50034, Colombia
  • Sociedad De Oncologia Y Hematologia Del Cesar ( Site 0404)
    Valledupar, Cesar Department 200001, Colombia
  • Administradora Country S.A.S - Clínica del Country ( Site 0407)
    Bogotá, Cundinamarca 110221, Colombia
  • IMAT S.A.S ( Site 0409)
    Montería, Departamento de Córdoba 230002, Colombia
  • Rigshospitalet University Hospital Copenhagen ( Site 1000)
    Copenhagen, Capital Region 2100, Denmark
  • Hopital La Timone ( Site 0503)
    Marseille, Bouches-du-Rhone 13385, France
  • Centre de Cancerologie du Grand Montpellier ( Site 0508)
    Montpellier, Herault 34070, France
  • Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 0510)
    Clermont-Ferrand, Puy-de-Dome 63003, France
  • Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen ( Site 0509)
    Rouen, Seine-Maritime 76038, France
  • Institut Gustave Roussy ( Site 0505)
    Villejuif, Val-de-Marne 94800, France
  • Institut Curie ( Site 0500)
    Paris, 75005, France
  • Soroka Medical Center-Oncology ( Site 0604)
    Beersheba, 8400000, Israel
  • Rambam Health Care Campus-Oncology Division ( Site 0602)
    Haifa, 3109601, Israel
  • Hadassah Medical Center. Ein Kerem ( Site 0601)
    Jerusalem, 9112001, Israel
  • Chaim Sheba Medical Center ( Site 0600)
    Ramat Gan, 5265601, Israel
  • Oslo universitetssykehus, Radiumhospitalet ( Site 1102)
    Oslo, 0379, Norway
  • Unidade Local de Saude Gaia/Espinho - Hospital Eduardo Santos Silva ( Site 1401)
    Vila Nova de Gaia, Porto District 4434-502, Portugal
  • Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 1400)
    Porto, 4200-072, Portugal
  • MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 1703)
    Bucharest, Bucharest 013823, Romania
  • Spitalul Clinic Colțea ( Site 1708)
    Bucharest, Bucharest 030171, Romania
  • Cardiomed SRL Cluj-Napoca ( Site 1701)
    Cluj-Napoca, Cluj 400015, Romania
  • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1702)
    Cluj-Napoca, Cluj 400015, Romania
  • S.C. Radiotherapy Center Cluj S.R.L ( Site 1706)
    Floreşti, Cluj 407280, Romania
  • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1704)
    Craiova, Dolj 200542, Romania
  • Cabinet Medical Oncomed ( Site 1707)
    Timișoara, Timiș County 300239, Romania
  • Seoul National University Bundang Hospital ( Site 1801)
    Seongnam, Kyonggi-do 13620, South Korea
  • Ajou University Hospital ( Site 1802)
    Suwon, Kyonggi-do 16499, South Korea
  • Severance Hospital Yonsei University Health System ( Site 1800)
    Seoul, 03722, South Korea
  • Samsung Medical Center ( Site 1803)
    Seoul, 06351, South Korea
  • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0700)
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
  • HOSPITAL CLÍNIC DE BARCELONA ( Site 0707)
    Barcelona, Catalonia 08036, Spain
  • Centro Oncologico de Galicia ( Site 0706)
    A Coruña, Galicia 15009, Spain
  • Hospital General de Valencia ( Site 0703)
    Valencia, Valenciana, Comunitat 46014, Spain

Showing the first 100 of 120 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10. PubMed 33300372 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in May 2024, 45 months.

Results were first posted in May 2025, 11 months after primary completion.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 45 months is close to that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2020
First posted
Jun 11, 2020
StartActual
Aug 6, 2020
Primary completionActual
May 31, 2024
CompletionActual
Oct 30, 2025
Results first posted
May 25, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04428151
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Aug 6, 2020
Primary completion
May 31, 2024
Completion
Oct 30, 2025
Results posted
May 25, 2025
Last update
Dec 4, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Pembrolizumab

Start the discussion